> GENR – I thought your argument about Evizon was that systemic admin would cause side effects. I guess as you follow the story you can adapt your story and still sound like you got it right from the start.<
This may be too advanced a concept for you to grasp, but concern about Evizon’s systemic side effects and concern about Evizon’s tepid efficacy are two sides of the same coin. With a systemic anti-angiogenic treatment for AMD, you’re between a rock and a hard place. If the inhibition of angiogenesis is strong, you’re screwed on side effects; if the inhibition of angiogenesis is weak, you’re screwed on efficacy.
This is why no other company is pursuing a systemic treatment for AMD. Only GENR is.
Market Data 
Markets 
AI
